Simons A D, Murphy G E, Levine J L, Wetzel R D
Arch Gen Psychiatry. 1986 Jan;43(1):43-8. doi: 10.1001/archpsyc.1986.01800010045006.
Seventy patients with nonbipolar affective disorder who completed a 12-week course of either cognitive therapy (CT), pharmacotherapy, CT plus active placebo, or CT plus pharmacotherapy were assessed one month, six months, and one year after termination of active treatment. Of the 44 patients who had originally responded to treatment, 16 relapsed as defined by reentry into treatment or by self-reported depression scores in the moderately depressed range. Twenty-eight patients remained well during the one-year follow-up. Patients with relatively high levels of remaining depressive symptoms on completion of treatment relapsed more often than those who had little or no residual depression. Further, at treatment termination, patients who relapsed had significantly higher scores on a measure of dysfunctional attitudes. Patients who had received CT (with or without tricyclic antidepressants) were less likely to relapse in the one-year follow-up period than patients who received pharmacotherapy.
70名患有非双相情感障碍的患者完成了为期12周的认知疗法(CT)、药物治疗、CT加活性安慰剂或CT加药物治疗疗程,在积极治疗结束后1个月、6个月和1年进行了评估。在最初对治疗有反应的44名患者中,有16名复发,复发定义为重新接受治疗或自我报告的抑郁评分处于中度抑郁范围。28名患者在一年的随访期间病情保持良好。治疗结束时仍有相对较高水平抑郁症状的患者比几乎没有或没有残余抑郁的患者更容易复发。此外,在治疗结束时,复发患者在功能失调态度量表上的得分显著更高。在一年的随访期内,接受CT(无论是否联合三环类抗抑郁药)的患者比接受药物治疗的患者复发的可能性更小。